RxDoctor Payments DataLook up a doctor →

David Park, MD

Medical Oncology · Fullerton, CANPI 1275619447

Payments from drug & device makers

$4,666,808in general payments, 2019–2025

Across 1,219 payments — averaging $3828.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$721K
  • Beigene, Ltd.$641K
  • E.r. Squibb & Sons, L.L.C.$470K
  • Gilead$414K
  • Merck$406K
  • Mirati Therapeutics, Inc.$384K
  • plus $1.6M from 54 others
$132in research payments, 2019–2025

Across 1 payment — averaging $132.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$132

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)113$720,758
Beigene, Ltd.50$640,901
E.r. Squibb & Sons, L.L.C.22$469,577
Gilead26$414,065
Merck135$406,414
Mirati Therapeutics, Inc.59$384,023
Eli Lilly6$227,767
Novocure Inc.50$222,651
Astellas Pharma Global Development40$139,282
Hoffmann-la Roche Limited15$129,127
Exelixis Inc.56$114,895
Novocure GmbH30$102,492
Novartis40$92,455
Ipsen Bioscience Inc.27$88,713
Pfizer49$75,773
AbbVie32$64,060
AVEO Pharmaceuticals, Inc.29$50,890
Amgen13$50,639
Regeneron7$46,768
Partner Therapeutics, Inc.3$37,927
Incyte Corporation58$32,479
QED Therapeutics, Inc.10$29,599
Astrazeneca UK Limited1$28,625
Daiichi Sankyo Inc.61$23,155
Halozyme Inc7$22,547
Acerta Pharma LLC1$21,760
Clovis Oncology, Inc.6$5,141
Johnson & Johnson34$3,246
Eisai Inc.16$3,007
EMD Serono, Inc.2$2,809
Ipsen Biopharmaceuticals, Inc4$2,147
Taiho Oncology, Inc.2$2,116
Array Biopharma Inc10$2,031
GSK4$2,008
Beigene USA, Inc.5$1,715
Bristol Myers Squibb41$650
Pharmacyclics LLC, An Abbvie Company27$378
Accuray Incorporated2$308
Tesaro, Inc.3$256
Astellas Pharma US Inc12$254
Takeda Pharmaceuticals U.S.A., Inc.10$245
Histosonics, Inc.1$228
Boehringer Ingelheim10$218
Genentech USA, Inc.8$191
Karyopharm Therapeutics Inc.7$188
Lexicon Pharmaceuticals, Inc.2$179
Stryker1$169
Seagen Inc.7$157
Puma Biotechnology, Inc.7$153
Steris Corporation1$137
Regeneron Healthcare Solutions, Inc.4$126
Beone Medicines USA, Inc.4$120
Lilly USA, LLC6$119
Endogastric Solutions, Inc1$118
Telix Pharmaceuticals3$114
Comsort, Inc1$100
Sanofi5$90
Coherus Oncology, Inc.4$83
Jazz Pharmaceuticals Inc.3$76
Servier Pharmaceuticals LLC3$75

How this compares

$4,666,808 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$185,855
Medicare patients
409
Services billed
1,584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Fullerton

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →